Pellucid Marginal Corneal Degeneration
9
2
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea
Safety and Effectiveness of the PXL-Platinum 330 System
Scleral Versus Corneal RGP Contact Lenses in Irregular Cornea Disorders